Suchergebnisse - "F0P408N6V4"

PubPharm (3.679)

21

Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma : a single-arm phase II trial

enthalten in: Nature communications | 2024

von Park, C. | Lee, H. | Kang, K. | +16

22

Bayesian interim analysis for prospective randomized studies : reanalysis of the acute myeloid leukemia HOVON 132 clinical trial

enthalten in: Blood cancer journal | 2024

von van der Maas, N. | Versluis, J. | Nasserinejad, K. | +14

23

Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide

enthalten in: Blood cancer journal | 2024

von Goel, U. | Charalampous, C. | Kapoor, P. | +18

24

Treatment-emergent mutations in myelodysplastic syndrome with del(5q) - lenalidomide related or disease-intrinsic clonal evolution?

enthalten in: Blood cancer journal | 2024

von Abdallah, M. | Reichard, K. | Gangat, N. | +1

25

Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma : An open label, phase 2 study

enthalten in: Cancer | 2024

von Gordon, M. | Feng, L. | Strati, P. | +20

26

Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7

enthalten in: Leukemia | 2024

von Kann, M. | Schneider, E. | Almazan, A. | +10

27

Combining lenalidomide with erythropoiesis stimulating agents : a party of one

enthalten in: Leukemia | 2024

von Chandhok, N. | Sekeres, M.

28

Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden : An analysis using linked Nordic registries

enthalten in: European journal of cancer (Oxford, England : 1990) | 2024

von Abildgaard, N. | Anttila, P. | Waage, A. | +7

29

New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma

enthalten in: Hematology/oncology clinics of North America | 2024

von Abdallah, N. | Kumar, S.

30

Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma : A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Oriol, A. | Dimopoulos, M. | Schjesvold, F. | +12